I read the SA article but I won't post it here. It was just what I was expecting. I found the following comment more believable and interesting:

"tank1967
Today, 7:51 AM

Comments (89)
|
The fact this article is negative toward Cytodyn management doesn’t surprise me. It focuses on current messaging and the inability to get the BLA file for HIV Combination Therapy. They want to dig up the past because the future is so bright. This is a paid article to bash the company. The timing is predictable and there be more hacks likes this guy taking shots a Cytodyn in the coming weeks. The question is with the DOJ investigation into short selling in conjunction with the manipulation of stock prices. The question lies to who paid this author? Is he or she working for a group of people trying to manipulate Cytodyn’s price? Sooner or later, the DOJ will look into the manipulation of Cytodyn’s stock. The stock is so heavily manipulated by entities who don’t want Leronlimab to hit the market. Gilead Sciences should have purchased Cytodyn years ago, but chose a different route. Cytodyn’s management understands what they have in Leronlimab and cannot be bought for pennies on the dollar. Nash data is set to hit and streets soon and this should scare Gilead. Cytodyn will have plenty of money to finish off HIV and eventually the market from them. I believe Gilead will be entrenched in their own DOJ investigation for the approval of Remdesivir. A garbage drug recycled for COVID. It does More harm than good! If there was no threat or manipulation going on, why write this article? Paid to manipulate the SP. Let’s see who get’s the last laugh."